Prospects for Bio-Thera's golimumab biosimilar

23 June 2021

China’s Bio-Thera Solutions has recently initiated a Phase III trial of its proposed golimumab biosimilar BAT2506 in China and Eastern Europe. Against this backdrop, BAT2506 is the first subcutaneous golimumab biosimilar, referencing Johnson & Johnson (NYSE: JNJ) Janssen’s Simponi, to enter a Phase III trial in multiple countries.

It has the potential to be the first golimumab biosimilar to gain approval in China and Europe following successful clinical trials, finds GlobalData, a leading data analytics and research company.

According to GlobalData’s ‘Pharmaceutical Intelligence Center’ (as of June 22, 2021), only two companies – Bio-Thera Solutions and Reliance Life Sciences – are investigating golimumab biosimilars in Phase III trials. Reliance Life Sciences is conducting a Phase III trial in India.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK